Dan Weiner, MD PhD (@danweiner92) header
Dan Weiner, MD PhD (@danweiner92) profile picture

PGY-2 @mghmedres via @harvardMITmdphd @broadinstitute \\ incoming @MGHCVFellows \\ human genetics in complex traits

Boston, MA
Joined August 2011
Photo by Dan Weiner, MD PhD (@danweiner92)Photo by Dan Weiner, MD PhD (@danweiner92)Photo by Dan Weiner, MD PhD (@danweiner92)Photo by Dan Weiner, MD PhD (@danweiner92)Photo by Dan Weiner, MD PhD (@danweiner92)Photo by Dan Weiner, MD PhD (@danweiner92)Photo by Dan Weiner, MD PhD (@danweiner92)Photo by Dan Weiner, MD PhD (@danweiner92)Photo by Dan Weiner, MD PhD (@danweiner92)Photo by Dan Weiner, MD PhD (@danweiner92)
Dan Weiner, MD PhD retweeted
How often is autism caused by de novo changes to the genome? What is the spectrum of penetrance across autism-associated genes? What can we expect from future autism gene discovery? I'm pleased to share a new preprint where we develop new statistical methods to answer these Qs.
1
21
3
61
6,346
Inflammation = causal risk factor for MI. While CRP (inflammatory marker) is dynamic over time, often a single measure is used for MI risk. How stable is CRP? How does MI risk vary with repeat CRP measures? We explore this in new @AJPCardio sciencedirect.com/science/ar… (1/6)
2
13
1
37
4,418
Our findings suggest that serial CRP measures may help to personalize risk stratification in ASCVD. Many open questions, including timing for serial checks. Excited to see development of inflammatory risk-stratification and therapeutic targeting in ASCVD in years ahead. (5/6)
1
1
1
155
Big thanks to @pnatarajanmd and co. for guidance through this project! Will be at @ACCinTouch and excited to discuss further! (6/6)
2
132
Just as most heritability resides in variation ⬇️ genome-wide significance thresholds, so exists meaningful transcriptional variation in genes individually not identified as a genomewide sig. This new method TRADE from @NadigAjay @Luke0connor characterizes those effects!
How do genetic perturbations change cells? How are these effects shaped by cell type and dosage? How do we best extract insight from modern massive perturbation atlases? Im pleased to share a new preprint where we develop a suite of statistical approaches to these Qs (link below)
1
4
1,532
We've noticed some common missteps when using Burden Heritability Regression (BHR) If you're using BHR, take a look at this new FAQ to avoid them! github.com/ajaynadig/bhr/wik…
2
17
3,075
Dan Weiner, MD PhD retweeted
New episode out this morning!! Today @GFPtagged + @danweiner92 tell the remarkable story of one scientist's very personal journey to find a treatment for hyperemesis gravidarum (@DrFejzo @HGmoms) Listen wherever you get your podcasts, or link below: player.captivate.fm/episode/…
1
3
449
Wegovy is effective, but no Medicare coverage. Easy to assume because of high $. But all obesity meds = 30y restriction. Today in @statnews, I discuss how ban emerged in a very different environment and argue we should recognize origins of status quo. statnews.com/2024/01/08/weig…
1
2
19
2,556
Dan Weiner, MD PhD retweeted
Can we precisely rewrite the genetic code - make a single DNA spelling change - in the liver of a human being for clinical effect? YES! Scientific milestone: VERVE-101 provides first proof-of-concept for in vivo DNA base editing in humans Clinical implication: It’s early but could open the way for an entire new way to treat heart disease; instead of daily pills/intermittent injections, a one-time intravenous infusion procedure to durably (possibly lifelong) lower LDL cholesterol; "surgery without a scalpel" Takeaways: 1. 10 patients with severe HeFH and ASCVD treated so far across 4 dose levels 2. Clinical effect on LDL-C (40% - 55% reductions) at potentially therapeutic doses 3. Dose-dependent reductions in blood PCSK9 protein and blood LDL-C 4. Durability so far out to six months, consistent with the pre-clinical data in NHP where the durability is out to 2.5y after a single treatment 5. Consistent with FDA guidance on patients to enroll in a Phase 1 study of gene editing products, we enrolled the sickest of the sick coronary disease patients 6. Safety profile revealed expected LNP-infusion related events: a) transient flu-like symptoms for a few hours after infusion; b) transient, reversible rise in LFTs after infusion 7. Two patients experienced CV events consistent with their underlying severe ASCVD 8. Safety profile supports continued development (DSMB have reviewed these data and requested to continue dosing) 9. These interim heart-1 data were submitted to FDA as part of IND package and we now have clearance to start study in U.S. 10. Next steps: finish dose escalation, complete dose expansion in 2024 11. Phase 2 start in 2025 for PCSK9 program Foremost, grateful to the patients who have volunteered and their families Thankful to the amazing @VerveTx scientific and clinical team (led by @andrew Bellinger), the investigators and study staff, the independent DSMB, and our partners P.S. Deepavali celebrates new knowledge and so thrilled to add today to our knowledge on the intersection of gene editing technology and cardiovascular disease $VERV @AHAScience @AHAMeetings @American_Heart #AHA23
40
231
67
967
342,756
Dan Weiner, MD PhD retweeted
I'm delighted to release the first half of my new open-access online textbook in human population genetics: web.stanford.edu/group/pritc…
59
1,043
61
3,634
683,881
Dan Weiner, MD PhD retweeted
Out today @Nature – our analysis of the influences of common nuclear DNA variation on mitochondrial DNA copy number and heteroplasmy across >250,000 people across two biobanks! disq.us/t/4ibyjjo
14
47
2
189
31,937
Everyone should apply to be a part of this brilliant new HMS lab. Huge congrats Luke!
Thrilled to announce: I'm starting a faculty position in the HMS Department of Biomedical Informatics @HarvardDBMI! The O'Connor Lab is crossing the river. 1/
3
3
1,548
Dan Weiner, MD PhD retweeted
We're excited to share a new podcast this morning! Today, @GFPtagged + @danweiner92 discuss new research on the single most important genetic risk factor for Alzheimer's and its therapeutic potential. Listen wherever you get podcasts, or here 👇 player.captivate.fm/episode/…
1
2
492
🔑 Reason 1: Common + rare variants = convergent: Drugs targeting RV associated genes can benefit many patients, not only the few who carry specific mutations 🔑 Reason 2: RV genetic architecture less polygenic -> Disease mechanisms involve attainable number of genes (14/15)
1
1
15
1,551
Huge shoutout to the dream team: @NadigAjay and @Luke0connor Our collaborators (especially @konradjk) and the UK Biobank for making this sort of work possible! Give BHR a try and let us know what you think! (15/15)
1
6
1,515